儿童免疫介导性疾病的共享遗传架构与治疗靶点
该研究对24种儿童期发病的免疫介导性炎症性疾病(IMIDs)进行全基因组关联分析,纳入18,086例病例和131,019例欧洲 ancestry 对照。研究发现SNP-based遗传力从过敏性疾病28.9%到自身免疫性疾病61.9%不等,识别出39个MHC区域外全基因组显著位点(含15个新位点),并发现儿童与成人IMIDs共享广泛多基因架构,优先指数分析识别出178个高评分基因,其中43个为已批准或研究中的IMID药物靶点。
要点
- 儿童IMIDs的SNP-based遗传力为28.9%至61.9%,自身免疫类别最高。
- MHC区域外发现39个全基因组显著位点,其中15个为新位点,19个跨类别共享。
- 优先指数识别178个高评分基因,43个为已批准或研究中的IMID药物靶点。
核心结论
- 儿童期发病IMIDs与成人形式共享核心通路,但具有由年龄特异性免疫和神经发育生物学塑造的独特遗传架构。
研究设计与样本
- 对24种儿童IMIDs(分类为自身免疫、多基因自身炎症、混合模式或过敏)进行全基因组关联分析,纳入18,086例病例和131,019例欧洲 ancestry 对照。
主要发现
- SNP-based遗传力范围为28.9%(过敏性疾病)至61.9%(自身免疫性疾病)。
- 遗传相关和多基因建模支持类别间部分共享及类别特异性组分。
- Meta分析识别MHC区域外39个全基因组显著位点,其中15个既往未报道,19个为类别间共享。
- 基因优先级和蛋白互作分析识别以MHC为中心的抗原呈递核心网络及类别富集模块。
- 儿童与成人IMIDs共享广泛多基因架构,顶级基因与成人风湿病强烈汇聚。
关键数值与推荐
- 优先指数分析识别178个高评分基因,包括43个已批准或研究中的IMID药物靶点。
- 富集通路包括NF-κB信号、Th17相关通路、JAK-STAT信号、PD-1/PD-L1、CTLA-4调控和破骨细胞分化。
临床怎么用
- 为儿童精准医学提供基因组框架,指导疾病分类、风险预测和治疗开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Paediatric-onset immune-mediated inflammatory diseases (IMIDs), including juvenile idiopathic arthritis and related rheumatic diseases, remain genetically undercharacterised. We aimed to define shared and category-specific genetic architecture across paediatric IMIDs, compare signals with adult IMIDs, and identify therapeutic opportunities. METHODS: We analysed 24 paediatric IMIDs classified as autoimmune, polygenic-autoinflammatory, mixed-pattern, or allergic. Genome-wide association analyses included 18,086 cases and 131,019 controls of European ancestry. We estimated single nucleotide polymorphism (SNP)-based heritability, genetic correlations, and polygenic overlap; performed subset-based meta-analysis; and conducted functional annotation, gene prioritisation, pathway and protein network analyses, adult-IMID comparison, and drug-target prioritisation. RESULTS: SNP-based heritability ranged from 28.9% for allergic IMIDs to 61.9% for autoimmune IMIDs. Genetic correlation and polygenic modelling supported partial sharing across categories with category-specific components. Meta-analysis identified 39 genome-wide significant loci outside the Major Histocompatibility Complex (MHC) region, including 15 previously unreported loci; 19 loci were shared between categories. Gene-prioritisation and protein interaction analyses identified a core MHC-centred antigen-presentation network, with category-enriched modules involving complement, innate/barrier pathways, epithelial biology, and type 2 immunity. Enriched pathways included nuclear factor κB signalling, T helper 17 related pathways, Janus kinase-signal transducer and activator of transcription signalling, programmed cell death protein 1/programmed death‑ligand 1, cytotoxic T‑lymphocyte associated protein 4 regulation, and osteoclast differentiation, several of which are relevant to rheumatic diseases. Paediatric IMIDs shared broad polygenic architecture with adult IMIDs, whereas top-ranked genes converged strongly with adult rheumatic diseases. Priority Index analysis identified 178 high-scoring genes, including 43 approved or investigational IMID drug targets. CONCLUSIONS: Paediatric-onset IMIDs share core pathways with adult forms but exhibit distinct genetic architecture shaped by age-specific immune and neurodevelopmental biology. These findings provide a genomic framework for paediatric precision medicine, guiding classification, risk prediction, and therapeutic development.
引用
- Li J, Qu HQ, March ME, et al. Shared genetic architecture and therapeutic targets across paediatric immune-mediated diseases. Ann Rheum Dis. 2026. PMID: 42575758. doi:10.1016/j.ard.2026.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。